Elsevier

Neuropharmacology

Volume 28, Issue 1, January 1989, Pages 89-97
Neuropharmacology

Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain

https://doi.org/10.1016/0028-3908(89)90073-7Get rights and content

Abstract

Drugs administered during the perinatal period reach the developing organism at the vulnerable stage of intensive brain histogenesis and cytodifferentiation. They may interfere with the programme of developmental processes in the brain and lead to disturbances at the cellular/subcellular level and to biochemical alterations. These abnormalities form the basis for the functional pathology which becomes apparent gradually during maturation or even in adulthood as neuropsycho-behavioural deviations.

A model experimental study in rats was carried out with synthetic glucocorticoids, which are widely used in obstetrics and neonatology for the prevention and treatment of neonatal idiopathic respiratory distress syndrome. As the developmental stage of the brain of the human foetus in late pregnancy closely resembles the ontogenetic phases of the brain of the rat in the early postnatal period, the neonate rat was taken as a model. The administration of dexamethasone to 7-day-old rats resulted in significant depletion of glucocorticoid receptors from the cytosol of the brain in a dose-dependent manner, beginning with the dose of 0.04 mg/kg (s.c.), i.e. a dose one order lower than the clinical dose used in obstetrics (0.4–0.5 mg/kg). Long-term follow-up of a single neonatal injection of dexamethasone (0.2 or 1 mg/kg s.c. on postnatal day 7) revealed an acceleration of some developmental landmarks in the preweaning period (incisor eruption, eye opening, motor skill) on the one hand, but a retardation of body growth and vaginal opening on the other hand. Adult animals exhibited a deficit in motor co-ordination, behavioural deviations (hyperactivity with stereotypy, decreased adaptability, increased emotional reactivity) and disturbances in reproduction in both males and females. Maldevelopment of the brain appeared in terms of retardation in growth with permanent deficit in weight of the cerebellum, reduced size of cells in the cerebellum and hippocampus and decreased concentration of noradrenaline in the hypothalamus. As all the deviations described were induced by a single neonatal injection of doses corresponding to the clinical dose in obstetrics and neonatology, a high behavioural tetatogenic risk of using glucocorticoids in the perinatal period may be expected.

References (35)

  • P.L. Ballard et al.

    Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome

    J. clin. Invest.

    (1975)
  • R.A. Ballard et al.

    Long-term outcome after prenatal glucocorticoid therapy

    Clin. Res.

    (1985)
  • O. Benešová et al.

    Brain glucocorticoid receptors and their role in behavioural teratogenicity of synthetic glucocorticoids

    Arch. Toxic.

    (1985)
  • O. Benešová et al.

    Brain Maldevelopment and Drugs

    (1984)
  • M.C. Bohn

    Glucocorticoid induced teratologies of the nervous system

  • M.C. Bohn et al.

    The effects of neonatal hydrocortisone on rat cerebellar development

    Dev. Neurosci.

    (1978)
  • Collaborative Group on Antenatal Steroid Therapy

    Effects of antenatal dexamethasone administration in the infant: long-term follow-up

    J. Pediat.

    (1984)
  • Cited by (0)

    View full text